FOXO3 and breast carcinoma: For example, Li et al. showed that circ_0002483 enhanced paclitaxel sensitivity in NSCLC by targeting GRB2, FOXO1, and FOXO3 via miR-182-5p.121 Sang et al. found that Hsa_circ_0025202 could inhibit tumor progression and enhance the sensitivity of cancer cells to tamoxifen in breast cancer via targeting miR-182-5p/FOXO3a axis.122 Moreover, Liang et al. indicated that decreased expression of circKDM4C in breast cancer suppressed DOX resistance through miR-548p/PBLD pathway.123 The roles and the molecular mechanisms of noncoding RNAs in cancer drug resistance are outlined in Table 2.